Actively Recruiting
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
Led by The First Hospital of Jilin University · Updated on 2025-12-30
1084
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
CONDITIONS
Official Title
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Clinically diagnosed acute ischemic stroke and received standard dose (0.25 mg/kg) of tenecteplase IV thrombolysis within 4.5 hours of onset
- Total National Institute of Health stroke scale (NIHSS) score 4 or higher, or single limb motor item score 2 or higher, and total NIHSS 15 or less after IV thrombolysis
- Tirofiban or placebo treatment can be started within 6 hours after IV thrombolysis
- Modified Rankin Scale (mRS) score before stroke onset 1 or less
- No intracranial hemorrhage confirmed by CT head scan after IV thrombolysis
You will not qualify if you...
- Received or planned bridge therapy
- Large area of infarct involving one-third or more of the middle cerebral artery supply area shown by imaging
- Atrial fibrillation or suspected cardiac embolism
- Epileptic seizures
- Use of antiplatelet, anticoagulant, or fibrinolytic agents within 24 hours before enrollment
- Active bleeding or bleeding tendency after intravenous thrombolysis
- Recent bleeding events within 1 year including digestive system, urinary system, hemorrhagic retinopathy, or other systemic bleeding
- Severe kidney or liver failure indicated by abnormal lab values
- Life expectancy less than 3 months
- Pregnant or breastfeeding women
- Known allergy to tirofiban
- Participation in another clinical trial within 3 months prior to this study
- Unwillingness to be followed up or likely poor treatment compliance
- Other conditions deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The first hospital of Jilin University
Changchun, Jilin, China, 130000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here